{
Graham Doyle

People

}
001122334455554433221100
001122334455554433221100

ubs raises fresenius price target to 47 euros maintains buy rating

UBS has increased its price target for Fresenius from 40 to 47 euros while maintaining a "Buy" rating. Analyst Graham Doyle emphasized that the company's focus is shifting towards value creation rather than merely avoiding losses, and he believes that current market expectations are overly pessimistic regarding the biosimilars sector.
boerse.de
Euro Fresenius SE & Co. KGaA DEU Graham Doyle
Finance & Economy, Market Report
07:21 26.03.2025

ubs raises fresenius target price to 47 euros maintains buy rating

UBS has increased its target price for Fresenius SE from 40 to 47 euros while maintaining a "Buy" rating. Analyst Graham Doyle emphasized that the company's focus is shifting towards value creation rather than merely avoiding losses, and he believes that current market expectations are overly pessimistic, particularly regarding the biosimilars sector.
MarketScreener
Euro Fresenius SE & Co. KGaA DEU CHE Graham Doyle
Finance & Economy, Market Report
07:08 26.03.2025

ubs maintains buy rating for fresenius with target price of 40 euros

UBS has maintained its "Buy" rating for Fresenius, setting a target price of 40 euros. Analyst Graham Doyle highlighted the company's focus on the Helios Deutschland Performance Program and the positive impact of biosimilars, alongside updates regarding its reduced stake in Fresenius Medical Care.
finanzen.ch
Euro UBS AG Fresenius Medical Care AG DEU Graham Doyle
Business & Industry, Market Report
23:34 05.03.2025

ubs maintains buy rating for fresenius se with target price of 40 euros

UBS AG maintains a "Buy" rating for Fresenius SE, setting a target price of €40, as the company navigates various factors impacting its annual targets, including the Helios Deutschland Performance Program and biosimilars. The share price rose by 3.0% to €40.59, reflecting a 21.0% increase since the start of 2025, with a Q1 2025 results announcement scheduled for May 7, 2025.
finanzen.ch
Euro UBS AG Fresenius Medical Care AG DEU Graham Doyle
Finance & Economy, Market Report
18:13 05.03.2025

ubs maintains buy rating for fresenius with target price of 40 euros

UBS has maintained its "Buy" rating for Fresenius, setting a target price of 40 euros. Analyst Graham Doyle highlighted insights from the annual European Healthcare Conference, focusing on the Helios Deutschland Performance Program and the positive impact of biosimilars. Fresenius also clarified its future plans regarding its stake in Fresenius Medical Care following a recent reduction.
boerse.de
Euro DEU Graham Doyle
Finance & Economy, Market Report
17:30 05.03.2025

ubs maintains buy rating for fresenius se with target price of 40 euros

UBS has maintained a "Buy" rating for Fresenius SE, setting a target price of 40 euros. The medical group highlighted key factors influencing its annual targets, including the Helios Deutschland Performance Program and the impact of biosimilars. As of the latest trading session, Fresenius shares rose 3.0% to EUR 40.59, indicating a slight downside potential of 1.45% from the target price.
finanzen.at
Euro UBS AG DEU Graham Doyle
Finance & Economy, Market Report
17:22 05.03.2025

UBS maintains buy rating for Fresenius with target price of 40 euros

UBS has maintained a "buy" rating for Fresenius SE, setting a target price of 40 euros. Analyst Graham Doyle highlighted the company's annual targets, emphasizing the impact of the Helios Deutschland Performance Program and the positive influence of biosimilars. Additionally, Fresenius provided insights into its future stake in Fresenius Medical Care following a recent reduction.
t-online.de
Euro DEU Graham Doyle
Business & Industry, Market Report
17:20 05.03.2025

ubs maintains buy rating for fresenius with 40 euro target price

UBS has maintained its "buy" rating for Fresenius, setting a target price of 40 euros. The medical group's investor relations highlighted key factors influencing annual targets, including the Helios Germany Performance Program and the positive impact of biosimilars. Additionally, Fresenius provided insights on its future stake in Fresenius Medical Care following a recent reduction in holdings.
Investing.com Deutsch
Euro Fresenius Medical Care AG DEU Graham Doyle
Business & Industry, Market Report
17:20 05.03.2025

ubs maintains buy rating for philips with target price of 29 euros

UBS has maintained its "Buy" rating for Philips Electronics, setting a target price of 29 euros following insights from CFO Charlotte Hanneman. Analyst Graham Doyle noted that while the consumer medical technology sector in China is expected to remain stagnant, hospital investments in the USA are projected to perform well.
boerse.de
Euro PHILIPS ELECTRONICS N.V. NLD Graham Doyle Charlotte Hanneman
Finance & Economy, Market Report
12:38 05.03.2025

ubs maintains buy rating for philips with target price of 29 euros

UBS has maintained its "Buy" rating for Philips Electronics, setting a target price of 29 euros following an industry conference. Analyst Graham Doyle noted that the regional business outlook remains stable, with a focus on reducing the disparity between reported and adjusted earnings.
boerse.de
Euro PHILIPS ELECTRONICS N.V. NLD Graham Doyle
Finance & Economy, Market Report
22:24 04.03.2025
Trending
Subcategory
Corporate News Stock Market Updates Industry Trends Industry Mergers & Acquisitions Finance Mergers & Acquisitions Global Financial Events Banking Regulations Global Trade Developments Domestic Politics Retail and Consumer Goods Central Bank Actions CEO Changes Government Policies Market Analysis and Predictions Workplace Trends Startups & Entrepreneurship Elections & Campaigns Government Economic Policies Inflation and Monetary Impact Supply Chain Management
Countries:
USA CHE GBR CHN DEU ITA FRA IND JPN CAN VNM MEX SGP KOR ESP ARE AUS TWN HKG NLD
Companies:
Tesla, Inc. Barclays PLC JPMorgan Chase & Co. Deutsche Bank Money Market PP Apple Inc. UniCredit S.p.A. Banco BPM S.p.A. Credit Suisse Strategic Income I The Goldman Sachs Group, Inc. UBS Group AG SpaceXCoin USD BNP Paribas SA Lloyds Banking Group plc Banco Santander, S.A. CREDIT AGRICOLE Amazon.com, Inc. Credit Agricole Berkshire Hathaway Inc. Reinsurance Group of America, Incorporated Google Inc.
Currencies:
United States Dollar Euro British Pound Sterling Swiss Franc Chinese Yuan Indian Rupee Japanese Yen South Korean Won Canadian Dollar Australian Dollar Hong Kong Dollar Offshore Chinese Yuan Singapore Dollar Mexican Peso Vietnamese Đồng Indonesian Rupiah Thai Baht Norwegian Krone Swedish Krona Filipino Peso
People:
Donald Trump Elon Musk Susan P. Crawford Brad Schimel Sergio Ermotti Karoline Leavitt JD Vance Warren Buffett Andrea Orcel Jennifer Piepszak Robin Leopold Joe Biden Dan Ives Ursula von der Leyen Mike Waltzer Matt Gaetz Bret Baier Olivier Calvet Kamala Harris Valentina Za

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.